Pfizer Bilan de santé

Santé financière contrôle des critères 6/6

Pfizer possède un total de capitaux propres de ₹37.5B et une dette totale de ₹25.0M, ce qui porte son ratio d'endettement à 0.07%. Son actif total et son passif total sont ₹44.6B et de ₹7.1B. L'EBIT de Pfizer est ₹6.5B ce qui fait que son ratio de couverture des intérêts -4.1. Elle dispose de liquidités et de placements à court terme de ₹22.8B.

Informations clés

0.07%

Ratio d'endettement

₹25.00m

Dette

Ratio de couverture des intérêts	-4.1x
Argent liquide	₹22.81b
Fonds propres	₹37.51b
Total du passif	₹7.08b
Total des actifs	₹44.59b

Mises à jour récentes de la santé financière

Recent updates

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Aug 31

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Aug 07

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

May 25

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Feb 13

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Jan 17

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Mar 15

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Jul 20

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Mar 29

Calculating The Fair Value Of Pfizer Limited (NSE:PFIZER)

Feb 07

These 4 Measures Indicate That Pfizer (NSE:PFIZER) Is Using Debt Safely

Sep 23

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de PFIZER ( ₹30.5B ) dépassent ses passifs à court terme ( ₹6.0B ).

Passif à long terme: Les actifs à court terme de PFIZER ( ₹30.5B ) dépassent ses passifs à long terme ( ₹1.0B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: PFIZER dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de PFIZER a été réduit de 0.08% à 0.07% au cours des 5 dernières années.

Couverture de la dette: La dette de PFIZER est bien couverte par le flux de trésorerie opérationnel ( 16660.8% ).

Couverture des intérêts: PFIZER gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Pfizer Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

These 4 Measures Indicate That Pfizer (NSE:PFIZER) Is Using Debt Safely

Recent updates

Pfizer Limited Announces Executive Appointments, Effective November 7, 2024

Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)

High number of new directors

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Price target increased by 11% to ₹5,477

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers

Price target decreased to ₹5,749